Cough Without Fever

Overview

• Definition: Cough without fever refers to a persistent or acute expulsion of air from the lungs, typically without an accompanying elevation in body temperature (oral temperature < 38°C or 100.4°F). This symptom is a common presentation in primary care and often indicates non-infectious or chronic underlying conditions.
• Epidemiology: Cough is one of the most common reasons for primary care visits, accounting for an estimated 10-30% of all outpatient consultations. While acute febrile cough is frequently viral, cough without fever is more likely to be due to postnasal drip/upper airway cough syndrome (UACS), asthma, gastroesophageal reflux disease (GERD), or medication side effects. Chronic cough (lasting > 8 weeks in adults, > 4 weeks in children) without fever affects 5-10% of the population.
• Classification: Cough can be classified by duration:
  • Acute cough: < 3 weeks
  • Subacute cough: 3 to 8 weeks
  • Chronic cough: > 8 weeks in adults; > 4 weeks in children. Cough without fever primarily encompasses subacute and chronic coughs, though acute cough can also occur without fever (e.g., irritant exposure).

Pathophysiology

• Mechanism: The cough reflex is a complex defensive vagal-mediated reflex mediated by mechanical and chemical receptors throughout the respiratory tree, especially in the larynx, pharynx, and tracheobronchial tree. Afferent signals travel via the vagus, glossopharyngeal, and trigeminal nerves to a central cough center in the medulla. Efferent signals via the vagus, phrenic, and spinal nerves lead to forced inspiration, glottic closure, rapid increase in intrathoracic pressure, and explosive expulsion of air. Cough without fever often involves a sensitized cough reflex (e.g., in UACS, asthma, GERD) or direct irritation without an acute inflammatory febrile response (e.g., ACE inhibitors).
• Risk Factors:
  • Smoking: Active or passive exposure
  • Environmental irritants: Dust, pollution, chemical fumes
  • Allergies: Allergic rhinitis, asthma
  • Medications: Angiotensin-converting enzyme (ACE) inhibitors (occurs in 5-20% of users)
  • Gastroesophageal reflux: Acidic reflux can directly irritate airways or stimulate vagal reflexes.
  • Atopic diathesis: Increased susceptibility to allergic conditions.
  • Occupational exposures: Asbestos, silica, coal dust leading to chronic lung disease.
  • Underlying lung conditions: Bronchiectasis, interstitial lung disease.
• Protective Factors:
  • Avoidance of irritants: Smoking cessation, minimizing exposure to environmental pollutants.
  • Vaccinations: Influenza, pertussis, pneumonia (though these often present with fever initially, prevention reduces chronic sequelae).
  • Control of underlying conditions: Effective management of asthma, GERD, allergic rhinitis.
  • Good hygiene: Reducing exposure to respiratory pathogens.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Persistent cough: Dry or productive, often exacerbated by specific triggers (e.g., cold air, exercise, lying flat).
  • Absence of fever: Oral temperature < 38°C (100.4°F).
  • Variability: Cough characteristics may change based on the underlying etiology (e.g., nocturnal cough in asthma/GERD, throat clearing in UACS).
• Early Signs:
  • Throat irritation, tickle in the throat (UACS)
  • Wheezing, shortness of breath (asthma)
  • Heartburn, regurgitation (GERD)
  • Rhinorrhea, nasal congestion (UACS)
• Advanced Signs:
  • Hoarseness, vocal changes (laryngeal irritation, GERD)
  • Chest pain (severe cough, GERD)
  • Fatigue, sleep disturbance (chronic cough impact)
  • Incontinence (especially in women with severe cough)
  • Rib fractures (rare, severe chronic cough)
• Atypical Presentations:
  • Cough syncope: Fainting due to increased intrathoracic pressure and reduced cerebral blood flow during severe paroxysms.
  • Vomiting: Especially in children, post-tussive emesis.
  • Hemoptysis: Rarely with chronic cough, warrants immediate investigation for serious pathology.

Physical Examination

• Inspection:
  • General appearance: Observe for signs of distress, cyanosis (rare).
  • Nose/Throat: Posterior pharyngeal cobblestoning, presence of nasal discharge or polyps (UACS). Mucopurulent discharge (sinusitis).
  • Chest: Observe respiratory rate, pattern, accessory muscle use (mild, if present), signs of chronic lung disease (e.g., barrel chest, clubbing – rare in isolated cough without fever).
• Palpation:
  • Sinuses: Tenderness over frontal or maxillary sinuses (sinusitis).
  • Neck: Lymphadenopathy (uncommon in non-febrile, non-infectious cough). Tracheal deviation (rare).
• Special Tests:
  • Auscultation of lungs:
    • Clear lungs: Common finding, especially with UACS, GERD, or ACE inhibitor cough.
    • Wheezing: Suggests asthma or other obstructive airway disease.
    • Rhonchi/Crackles: May indicate bronchitis, bronchiectasis, or interstitial lung disease (less common without fever unless chronic).
  • Auscultation of heart: Evaluate for cardiac causes (e.g., heart failure causing cough, though often with dyspnea and other findings).
  • Postnasal drip examination: Use a tongue depressor to look for mucus streaming down the posterior pharynx.

Diagnostic Approach

History Taking

• Key Questions:
  • Duration of cough: Acute (<3 weeks), subacute (3-8 weeks), chronic (>8 weeks).
  • Character of cough: Dry, productive (color/consistency of sputum), barky, brassy.
  • Timing: Nocturnal, diurnal, seasonal, activity-related.
  • Associated symptoms: Rhinorrhea, sneezing, nasal congestion, postnasal drip sensation (UACS), heartburn, regurgitation, dysphagia (GERD), dyspnea, wheezing, chest tightness (asthma), hoarseness, voice changes.
  • Exacerbating factors: Allergens, cold air, exercise, specific foods, odors, lying flat, talking.
  • Relieving factors: Medications, position changes.
  • Medication history: Especially ACE inhibitors, beta-blockers, NSAIDs.
  • Smoking history: Current, former, passive exposure.
  • Occupational/environmental exposures: Dust, chemicals, pets.
  • Gastrointestinal symptoms: Heartburn, regurgitation, dyspepsia.
  • Allergy history: Seasonal allergies, eczema, asthma.
  • Travel history: For unusual infections (though fever more common).
  • Pertussis vaccination status: Especially important for subacute/chronic cough.
  • Impact on quality of life: Sleep disturbance, social embarrassment, fatigue.
• Red Flags:
  • Hemoptysis: Coughing up blood.
  • Unexplained weight loss: Suggests malignancy, chronic infection (e.g., TB).
  • New-onset dyspnea or worsening shortness of breath.
  • Recurrent pneumonia.
  • Persistent focal lung abnormality on examination.
  • Significant hoarseness or dysphonia (lasting > 3 weeks).
  • Risk factors for lung cancer: Heavy smoking history, significant environmental exposure.
  • Dysphagia, choking with meals.
  • Immuno-compromised status.
  • Cough onset with foreign body aspiration (especially in children).

Laboratory Tests

• First-Line:
  • None routinely indicated for acute non-febrile cough following viral illness or irritant exposure.
  • CBC with differential: May show eosinophilia in allergic conditions (asthma), but non-specific.
  • IgE levels/Allergy panel: If allergic rhinitis or asthma is suspected.
  • Pertussis PCR or serology: Consider in subacute/chronic cough, especially if exposure history or "whooping" cough characteristics (note, serology may be falsely negative early).
• Confirmatory:
  • Spirometry with bronchodilator challenge: If asthma is suspected (FEV1 increase >12% and >200 mL post-bronchodilator is diagnostic). Bronchial provocation test (e.g., methacholine challenge) if spirometry is normal but asthma still suspected.
  • 24-hour esophageal pH monitoring or impedance studies: Gold standard for diagnosing GERD-related cough when empiric PPI therapy fails.
  • Sputum culture and sensitivity: If productive cough with purulent sputum, suspicion of bacterial infection (e.g., chronic bronchitis, bronchiectasis). AFB stain and culture if TB suspected.
• Monitoring:
  • Peak flow monitoring: For asthma management.
  • Follow-up spirometry: To assess response to asthma therapy.
  • Repeat imaging/labs: As per diagnosis and treatment plan.

Imaging

• Recommended:
  • Chest X-ray (CXR) posteroanterior and lateral: Recommended for chronic cough (> 8 weeks) to rule out structural lung disease, mass, infiltrates, pleural effusion, or cardiomegaly. CXR is typically normal in UACS, asthma, GERD, and ACE inhibitor cough.
  • Sinus X-ray or CT scan of paranasal sinuses: If chronic sinusitis is suspected (maxillary, frontal, ethmoid opacity or air-fluid levels). CT is more sensitive.
• Advanced:
  • High-resolution computed tomography (HRCT) of the chest: Indicated if CXR is abnormal or if persistent cough with normal CXR and no identified cause after initial workup, to look for bronchiectasis, interstitial lung disease, subtle masses, or lymphadenopathy.
  • Barium swallow/Upper GI series: If anatomical abnormalities of the esophagus or aspiration are suspected.
  • Bronchoscopy: If localized airway obstruction, foreign body, or malignancy is suspected and other investigations are inconclusive; also used for bronchoalveolar lavage (BAL) or biopsies.
  • Esophagogastroduodenoscopy (EGD): If GERD symptoms are severe or empiric therapy fails, to assess for esophagitis, strictures, or Barrett's esophagus.

Management

Acute Management

• Immediate: For acute cough without fever, often supportive care.
  • Hydration: Warm liquids, honey (for adults and children > 1 year).
  • Humidified air: May soothe irritated airways.
  • Cough suppressants: Dextromethorphan (10-20 mg q4-6h PRN in adults) or guaifenesin (expectorant, 200-400 mg q4h PRN) for symptomatic relief, efficacy is modest. Use judiciously and only for debilitating cough. Not recommended for children < 6 years.
• Stabilization:
  • If acute cough due to irritant exposure, remove from exposure.
  • If acute exacerbation of known asthma, appropriate inhaled bronchodilators (e.g., albuterol MDI 2-4 puffs q4-6h PRN).
• Emergency: Rarely required for cough without fever unless it precipitates syncope, significant respiratory distress (then likely not "without fever"), or hemoptysis. Manage underlying emergency (e.g., foreign body removal, management of severe hemorrhage).

Chronic Management

• Pharmacological: Based on underlying etiology:
  • Postnasal Drip/UACS:
    • First-generation antihistamine/decongestant combination: e.g., brompheniramine/pseudoephedrine (one tablet/dose q4-6h PRN) or diphenhydramine (25-50 mg q4-6h PRN).
    • Intranasal corticosteroids: e.g., fluticasone propionate (1-2 sprays per nostril daily) for allergic rhinitis/sinusitis.
    • Saline nasal irrigation: Regular use.
  • Asthma:
    • Inhaled corticosteroids (ICS): e.g., fluticasone (100-250 mcg BID) or budget (180-360 mcg BID) as maintenance.
    • Short-acting beta-agonists (SABA): e.g., albuterol (2-4 puffs q4-6h PRN) for rescue.
    • Long-acting beta-agonists (LABA): Added if ICS alone is insufficient (e.g., salmeterol/fluticasone combination).
    • Leukotriene receptor antagonists (LTRA): e.g., montelukast (10 mg daily) can be alternative or add-on.
  • GERD:
    • Proton pump inhibitors (PPIs): e.g., omeprazole 20-40 mg daily or BID for 8-12 weeks; may require longer duration for cough.
    • H2-receptor blockers: e.g., ranitidine (no longer widely available; famotidine 20-40 mg BID) as an alternative or add-on, especially for nocturnal symptoms.
  • ACE Inhibitor cough:
    • Discontinue ACE inhibitor: Substitute with an angiotensin receptor blocker (ARB) (e.g., losartan, valsartan). Cough typically resolves within 1-4 weeks but can take up to 3 months.
  • Non-specific chronic cough:
    • Gabapentin: 300 mg daily, titrating up to 900-1800 mg/day in divided doses. Can reduce cough reflex sensitivity. Drowsiness is a common side effect.
    • Pregabalin: 75 mg BID, titrating up to 300 mg/day.
    • Low-dose morphine: 5 mg daily (off-label, for severe refractory cases, specialist referral).
• Non-pharmacological:
  • Smoking cessation: Crucial for smokers.
  • Avoidance of irritants: Environmental triggers, allergens.
  • Dietary modifications for GERD: Avoid trigger foods (fatty foods, chocolate, caffeine, alcohol, acidic foods), elevate head of bed, avoid eating close to bedtime.
  • Speech therapy/Cough specific physiotherapy: For laryngeal irritation, vocal cord dysfunction, or retraining of the cough reflex.
  • Humidifiers, air purifiers: May help in some cases.
• Monitoring:
  • Regular follow-up to assess symptom resolution, medication side effects, and adjustment of therapy.
  • Spirometry monitoring for asthma control.
  • Continued evaluation for red flags if cough persists despite treatment for identified cause.

Treatment Algorithms

• First-Line: Follow a diagnostic and therapeutic algorithm based on the "big three" causes of chronic cough without fever after ruling out ACE inhibitor use and a normal CXR:
  1. Rule out ACEi cough: Ask specifically. If on ACEi, switch to ARB.
  2. Treat UACS empirically: Antihistamine-decongestant orally or intranasal steroids for 2-4 weeks. If improves, continue. If no improvement, proceed.
  3. Treat Asthma empirically: Initiate ICS ± SABA for 4-8 weeks, or perform spirometry with bronchodilator challenge for diagnosis. If improves, continue/monitor. If no improvement, proceed.
  4. Treat GERD empirically: PPI once or twice daily for 8-12 weeks. If improves, continue/monitor. If no improvement, proceed.
• Second-Line:
  • If the "big three" treatments fail or symptoms are atypical, perform advanced diagnostics (HRCT chest, specialty consultations).
  • Consider specific treatments for less common causes:
    • Bronchiectasis: Airway clearance techniques, antibiotics for exacerbations.
    • Interstitial lung disease: Immunosuppressants, anti-fibrotic agents guided by sub-type.
• Refractory Cases:
  • Re-evaluate diagnosis: Consider repeat imaging, consult pulmonologist, ENT, gastroenterologist.
  • Consider "non-specific chronic cough" or "chronic refractory cough" (CRC) diagnosis.
  • Neuromodulators: Gabapentin or pregabalin may be tried.
  • Cough suppressants: Opiates (codeine, morphine) can be considered by specialists for severe, debilitating cough, but with caution due to side effects and addiction potential.
  • Behavioral therapy: Cough suppression techniques, counseling.

Complications

• Common:
  • Hoarseness, sore throat.
  • Fatigue, sleep disturbance.
  • Musculoskeletal chest pain.
  • Urinary incontinence (especially in women).
  • Social embarrassment, anxiety.
• Serious:
  • Syncope: Cough-induced fainting.
  • Rib fractures: Rare but can occur with severe paroxysms.
  • Pneumothorax/Pneumomediastinum: Very rare, usually with forceful coughing and underlying lung pathology.
  • Gastric rupture: Extremely rare, related to extreme intrathoracic pressure.
• Long-term:
  • Development of irreversible lung damage (if untreated underlying cause like bronchiectasis).
  • Chronic pain.
  • Depression, anxiety due to persistent symptoms.

Prognosis

• Factors:
  • Underlying cause: Prognosis is excellent when an identifiable and treatable cause is found (e.g., ACE inhibitor discontinuation, good asthma control, GERD treatment).
  • Duration of cough: Acute cough usually resolves completely. Chronic cough can be challenging but often improves with targeted therapy.
  • Comorbidities: Presence of other chronic conditions can complicate management and prognosis.
  • Smoker status: Continued smoking worsens prognosis.
• Survival: Generally good for non-febrile cough as it's often not indicative of immediately life-threatening conditions. However, persistent untreated underlying pathologies (e.g., lung cancer, severe ILD) have their own guarded prognosis.
• Quality of Life: Chronic cough significantly impairs quality of life, affecting sleep, social interactions, work productivity, and emotional well-being. Effective management leads to substantial improvement.

Prevention

• Primary:
  • Smoking cessation: The most effective preventive measure for many chronic coughs.
  • Avoidance of environmental irritants: Air pollution, occupational hazards.
  • Allergen avoidance: For individuals with identified allergies.
  • Influenza and pneumococcal vaccinations: May prevent exacerbations of underlying respiratory conditions that could lead to chronic cough.
• Secondary:
  • Early diagnosis and treatment: Prompt management of conditions like asthma, GERD, and rhinitis to prevent progression to chronic cough.
  • Regular follow-up: For patients on medications that can cause cough (e.g., ACE inhibitors).
• Tertiary:
  • Comprehensive management of chronic diseases: Optimal control of asthma, COPD, GERD to prevent complications and reduce cough severity.
  • Pulmonary rehabilitation: For some chronic lung conditions.

Special Populations

• Pediatric:
  • Common causes: Post-infectious cough (often subacute), UACS, asthma, retained foreign body, pertussis, GERD.
  • CXR: Is often recommended earlier for chronic cough (>4 weeks) in children.
  • Pertussis: Important consideration.
  • Cystic Fibrosis: Should be considered in children with chronic productive cough and failure to thrive.
  • Aspiration: More common cause of chronic cough in young children (e.g., from neuromuscular disorders or swallowing dysfunction).
  • Dosages: All medication dosages must be adjusted for weight/age. Many adult cough/cold medications are contraindicated in children < 6 years.
• Geriatric:
  • Increased prevalence: More susceptible to chronic cough due to age-related changes, polypharmacy, and comorbidities.
  • Aspiration: Risk increased due to dysphagia, neurological conditions.
  • Cardiac cough: Heart failure is a more common cause in the elderly.
  • Medication side effects: More sensitive to sedative effects of antihistamines, opioids. ACE inhibitor cough is common.
  • Malignancy: Higher suspicion for lung cancer with new-onset chronic cough.
  • Presentation: May have less typical symptoms, or diminished cough reflex sensitivity leading to aspiration.
• Pregnancy:
  • Diagnostic approach: Minimize radiation exposure (limit CXR to vital indications).
  • Treatment: Avoid certain medications, e.g., pseudoephedrine in first trimester, many antihistamines. Consult with OB/GYN.
  • GERD: Commonly exacerbated during pregnancy due to hormonal changes and uterine pressure. First-line treatment non-pharmacological, then antacids, H2 blockers (e.g., ranitidine/famotidine), then PPIs (e.g., omeprazole, lansoprazole considered safe).
  • Pertussis vaccine: Recommended during each pregnancy (Tdap) to protect the newborn.
• Comorbidities:
  • Immunocompromised: Higher risk for opportunistic infections (e.g., PCP, fungal infections, TB) that can cause cough without fever initially. Require aggressive diagnostic workup.
  • Chronic kidney disease/Liver disease: May alter drug metabolism, requiring dosage adjustments.
  • Cardiac disease: Heart failure can present with cough, often with dyspnea, orthopnea, paroxysmal nocturnal dyspnea.

Clinical Pearls

• Diagnostic:
  • "The big three": Always consider UACS, asthma, and GERD as the most common causes of chronic cough without fever after ruling out ACE inhibitor use and interpreting a normal CXR.
  • Empiric therapy is key: Often, a sequential therapeutic trial for the "big three" is more efficient than extensive diagnostic testing, especially for chronic cough with normal CXR.
  • Pertussis: Do not forget to consider pertussis (whooping cough), especially in subacute/chronic cough that is paroxysmal and severe, even in vaccinated individuals.
  • ACE inhibitor inquiry: Always ask about ACE inhibitor use, even if the patient has been on it for years, as cough can develop late.
  • Non-smoker, normal CXR: If a non-smoker has a normal CXR and no ACE inhibitor use, the cause is almost always asthma, GERD, or UACS.
• Treatment:
  • Educate patients: Chronic cough treatment often requires patience and adherence to medication for weeks to months to see full effect.
  • Manage expectations: Complete resolution may not always be achievable, but significant improvement in quality of life is the goal.
  • Lifestyle modifications for GERD: Are as crucial as pharmacological agents.
  • Follow guidelines: Refer to global guidelines for asthma (GINA), rhinitis (ARIA), and GERD for optimal management.
• Pitfalls:
  • Over-reliance on symptomatic cough suppressants: Cough is a symptom, not a diagnosis. Suppressing it without addressing the underlying cause is rarely appropriate for chronic cough.
  • Missing ACE inhibitor cough: Forgetting to ask about or incorrectly dismissing ACE inhibitor use.
  • Prematurely stopping empiric therapy: Not giving adequate time (e.g., 2-4 weeks for UACS, 4-8 weeks for asthma, 8-12 weeks for GERD) for anti-reflux or anti-inflammatory drugs to work before concluding failure.
  • Ignoring red flags: Failing to pursue aggressive diagnostic workup when red flags are present.
  • Inadequate patient education: Patients get frustrated if they don't understand the long timeline for chronic cough resolution.

Recent Updates

• Guidelines:
  • ACCP Guidelines (American College of Chest Physicians): Regularly updated, comprehensive guidelines for the management of acute and chronic cough, emphasizing a systematic, evidence-based approach. The 2023 ACCP Cough Guidelines provide detailed recommendations for specific populations and etiologies.
  • British Thoracic Society (BTS) Cough Guidelines: Provide UK-specific recommendations, often aligning with ACCP.
  • European Respiratory Society (ERS) Guidelines: Offer complementary evidence-based recommendations for chronic cough management.
• Evidence:
  • Neuromodulators: Growing evidence supports the use of gabapentin and pregabalin as non-narcotic options for refractory chronic cough, likely by reducing hypersensitivity of the cough reflex.
  • Non-pharmacological interventions: Increasing recognition of the role of speech pathology and cough-specific physiotherapy in retraining the cough reflex and addressing laryngeal hypersensitivity.
  • Biologics: Emerging research on biologic therapies targeting type 2 inflammation for severe refractory asthma with cough, but not yet routine for isolated cough.
• Controversies:
  • Role of empiric therapy vs. aggressive workup: While empiric therapy for the "big three" is widely accepted, the optimal duration and sequence, as well as the threshold for early advanced imaging in non-responders, remain areas of discussion.
  • Chronic refractory cough (CRC): The pathogenesis is still under active investigation, with focus on neural hypersensitivity. Optimal management strategies are evolving.
  • Efficacy of OTC cough suppressants: Continued debate on the true efficacy of many over-the-counter cough and cold preparations, particularly for chronic cough and in pediatric populations.

Key References

• Guidelines:
  • Irwin, R. S., et al. (2023). Executive Summary: ACCP Guidelines for Chronic Cough. Chest, 163(1), 4-33. (Most recent comprehensive guideline)
  • Morice, A. H., et al. (2022). ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. European Respiratory Journal, 60(3), 2101875.
  • Chung, F., et al. (2006). British Thoracic Society guidelines for the management of chronic cough in adults. Thorax, 61(Suppl 1), i1-i24. (Older but foundational)
• Studies:
  • Ryan, N. M., et al. (2012). Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. The Lancet, 380(9853), 1583-1589.
  • Vertigan, A. E., et al. (2014). Efficacy of speech pathology management for chronic cough: a randomised placebo-controlled trial of two therapies. Thorax, 69(11), 990-997.
• Reviews:
  • Kardos, P., & Bachmann, M. O. (2020). Chronic cough: a comprehensive review. Respiratory Medicine, 172, 106121.
  • Dicpinigaitis, P. V., et al. (2014). An epidemiologic survey of chronic cough. Chest, 145(2), 295-300.

---

Disclaimer: This information is intended for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition. Clinical judgment is always paramount and should guide patient care decisions. Dosage recommendations are typical adult doses and may require adjustment based on individual patient factors, renal/hepatic function, and specific product formulations.